Dudediligence.

AnaptysBio, Inc

ANABNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$11.0MJun ’24$30.0MSep ’24$43.1MDec ’24$27.8MMar ’25$22.3MJun ’25$76.3MSep ’25$108.2MDec ’25$25.6MMar ’26
Net income, by quarter
−$46.7MJun ’24−$32.9MSep ’24−$21.8MDec ’24−$39.3MMar ’25−$38.6MJun ’25$15.1MSep ’25$49.6MDec ’25−$52.9MMar ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$63.2M$10.3M$17.2M$91.3M$234.6M
Operating income−$56.8M−$115.2M−$164.4M−$114.9M$226.9M
Net income−$57.8M−$128.7M−$163.6M−$145.2M−$13.2M
Operating cash flow−$45.9M−$73.6M−$120.8M−$135.3M$19.7M
Free cash flow−$47.3M−$74.0M−$121.6M−$135.7M$19.6M
Cash$495.7M$71.3M$36.0M$123.1M$238.2M
Shares outstanding27.6M28.5M26.6M30.5M28.0M